barriers to getting a glp-1 medication prescribed abandonment rates remain high despite booming demand Why we are changing coverage
Description
(Thats possible to do, but its a somewhat annoying extra step.) Since youll already be paying $20 to $40 per year for Shotsy, this is a notable drawback
Suicidality concerns: what we know now Regulatory reviews by the FDA and EMA have not found evidence that GLP-1s cause suicidal thoughts or behaviors, though monitoring continues (FDA, 2024
Practical considerations when switching Beyond the pharmacology, several practical factors influence which alternative works best in your daily life
In one study (again, with a standardized breakfast), at the five-month mark (i.e
